1-ethyl-2,2-dimethyl-butylamine | 861051-98-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-ethyl-2,2-dimethyl-butylamine
• 英文别名: 4-Amino-3.3-dimethyl-hexan；1-Aethyl-2,2-dimethyl-butylamin；4,4-Dimethylhexan-3-amine
• CAS: 861051-98-1
• 化学式: C₈H₁₉N
• 分子量: 129.246
• InChiKey: XBLCVGCWFRMTDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  9
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-ethyl-2,2-dimethyl-butylamine 、 异氰酸苯酯 在 乙醚 作用下， 生成 N-(1-ethyl-2,2-dimethyl-butyl)-N'-phenyl-urea
  参考文献：
  名称：

  289.脂肪族硝基化合物。第十部分格氏试剂对α-硝基烯烃的作用

  摘要：

  DOI：

  10.1039/jr9470001494
• 作为产物：
  描述：

  4,4-dimethyl-hexan-3-one oxime 在 甲醇 、 镍 作用下， 生成 1-ethyl-2,2-dimethyl-butylamine
  参考文献：
  名称：

  289.脂肪族硝基化合物。第十部分格氏试剂对α-硝基烯烃的作用

  摘要：

  DOI：

  10.1039/jr9470001494

文献信息

• Fabric care method
  申请人：——

  公开号：US20020119899A1

  公开（公告）日：2002-08-29

  The present invention provides a process for inhibiting the re-absorption of migrating dyes in the wash liquor, comprising introducing into a wash liquor containing a peroxide-containing detergent, from 0.5 to 150, preferably from 1.5 to 75, especially from 7.5 to 40 mg, per liter of wash liquor, of one or more compounds having the formula: 1 in which n is 1, 2 or 3; A is an anion; Y is —(CH 2 ) m in which m is an integer ranging from 1 to 8; —(CH 2 ) p —CH(R 1 )— in which p is an integer ranging from 1 to 7 and R 1 is linear or branched C 1 -C 4 -alkyl, preferably methyl; —CX═CX— in which X is cyano, linear or branched C 1 -C 8 -alkyl or di(linear or branched C 1 -C 8 -alkyl)-amino; —(CH 2 ) q —NR 1 —(CH 2 ) q — in which R 1 has its previous significance and q is 1, 2, 3 or 4; or a 1,2-cyclohexylene residue having the formula: 2 R is cyano; halogen; hydroxy; OR 1 in which R 1 has its previous significance; CO 2 R 2 in which R 2 is hydrogen or linear or branched C 1 -C 4 -alkyl; nitro; linear or branched C 1 -C 8 -alkyl; di-(C 1 -C 12 alkyl)amino; NR 3 R 4 in which R 3 and R 4 are the same or different and each is linear or branched C 1 -C 12 -alkyl; or —N ⊕ R 1 R 3 R 4 in which R 1 , R 3 and R 4 have their previous significance.

  本发明提供了一种抑制洗涤液中迁移染料再吸收的方法，包括将式1中的一种或多种化合物引入含有过氧化物的洗涤液中，每升洗涤液中含有0.5至150毫克，优选为1.5至75毫克，特别优选为7.5至40毫克，其中式1中，n为1、2或3；A为阴离子；Y为-(CH2)min，其中m为1至8的整数；-( )p-CH(R1)-，其中p为1至7的整数，R1为线性或支链的C1-C4烷基，优选为甲基；-CX═CX-，其中X为氰基，线性或支链的C1-C8烷基或二(线性或支链的C1-C8烷基)氨基；-( )q-NR1-( )q-，其中R1具有其前述意义，q为1、2、3或4；或式2中的1,2-环己基残基，其中R为氰基、卤素、羟基、OR1，其中R1具有其前述意义；CO2R2，其中R2为氢或线性或支链的C1-C4烷基；硝基；线性或支链的C1-C8烷基；二-(C1-C12烷基)氨基；NR3R4，其中R3和R4相同或不同，且均为线性或支链的C1-C12烷基；或—N⊕R1R3R4，其中R1、R3和R4具有其前述意义。
• Polymerization inhibitor and retarder compositions with amine stabilizer
  申请人：Ecolab USA Inc.

  公开号：US11180578B2

  公开（公告）日：2021-11-23

  Described are compositions and methods for inhibiting polymerization of a monomer (e.g., styrene) composition, which use an N—O polymerization inhibitor, a quinone methide polymerization retarder, and an amine stabilizer having a primary and/or secondary amine group. In a mixture, the amine-based stabilizer can prevent antagonistic effects and can provide greater antipolymerant activity. In turn, the mixture inhibits apparatus fouling and improves the purity of monomer streams.

  描述了抑制单体（如苯乙烯）组合物聚合的组合物和方法，其中使用了一种 N-O 聚合抑制剂、一种醌甲醚聚合延缓剂和一种具有伯胺和/或仲胺基团的胺稳定剂。在混合物中，胺基稳定剂可以防止拮抗作用，并提供更强的抗聚合活性。反过来，混合物可抑制装置堵塞，提高单体流的纯度。
• ZUSAMMENSETZUNG ZUR ARTHROSE-/ARTHRITISBEHANDLUNG, INSBESONDERE VON GELENKEN
  申请人：Trott, Katharina

  公开号：EP1689359A2

  公开（公告）日：2006-08-16
• COMPOSITION FOR INHIBITING MONOMER POLYMERIZATION COMPRISING A NITROXIDE INHIBITOR, A QUINONE METHIDE RETARDER AND AN AMINE STABILIZER
  申请人：Ecolab USA, Inc.

  公开号：EP3820846A1

  公开（公告）日：2021-05-19
• Bridged polycyclic compound based compositions for coating oral surfaces in humans
  申请人：Whiteford Jeffery A.

  公开号：US20090105262A1

  公开（公告）日：2009-04-23

  A pharmaceutically active agent, a pharmaceutically active agent carrier and method of use thereof are described. In some embodiments, a system may include a composition. The composition may include one or more bridged polycyclic compounds. At least one of the bridged polycyclic compounds may include at least two cyclic groups, and at least two pharmaceutically active agents may be associated with the bridged polycyclic compound. In some embodiments, one or more bridged polycyclic compounds may be applied to an oral surface of a human such that an oral malady may be inhibited and/or ameliorated.